Jonathan W. Friedberg, M.D.

See information for Patients. Viewing information for Researchers.

Contact

University of Rochester
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, New York 14642

Office: 585 273-4150

Fax: 585 273-5761

Current Appointments

Education
MS Clinical Investigation Harvard Medical School 2001
MD Medicine Harvard Medical School 1994
BA Biology Williams College 1990
Post-Doctoral Training & Residency
Postdoctoral Fellow, Clinical Investigator Training Program Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA. 1999 - 2001
Clinical Fellow in Medicine Harvard Medical School, Boston, MA 1997 - 1999
Hematology/Oncology Fellow Dana-Farber/Partners Cancer Care, Boston, MA Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital West Roxbury VA Medical Center 1997 - 1999
Senior Associate Resident in Medicine Massachusetts General Hospital, Boston, MA 1996 - 1997
Junior Assistant Resident in Medicine Massachusetts General Hospital, Boston, MA 1995 - 1996
Intern in Medicine Massachusetts General Hospital, Boston, MA 1994 - 1995
Recent Journal Articles
Showing the 5 most recent journal articles. (49 available)
Toothaker SR, Kelly J, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead , Thomas D, van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW. "Outcomes of patients with Burkitt lymphoma older than age 40 treated with aggressive chemotherapeutic regimens". Clinical Lymphoma and Myeloma in press (2009).
Friedberg JW, Cohen P, Chen L, Robinson K, Forero-Torres A, LaCasce A, Fayad L, Bessudo A, Camacho E, Williams M, van der Jagt R, Oliver J, Loh E, Cheson BD:. "Bendamustine in patients with rituximab-refractory and alkylator-refractory, indolent non-Hodgkin's lymphoma: results from a phase I multicenter, single-agent study." Jounal of Clinical Oncology 26 (2008): 204-10.
Friedberg JW, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher DC, Szot A, Van den Abbeele AD, Freedman AS. "Targeting the follicular lymphoma microenvironment through blockade of TNF-alpha with etanercept." Leukemia and Lymphoma 49 (2008): 902-09.
Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW. "Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma." Cancer Investigation 26 (2008): 431-3.
Mendler J, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW. "Bortezomib and gemcitabine in relapsed or refractory Hodgkin lymphoma." Annual Oncology 19 (2008): 1759-64.